Accurate Point of Care Liver Disease Diagnostics

Active, not recruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

August 3, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
NAFLDNonalcoholic Fatty Liver
Interventions
DIAGNOSTIC_TEST

Liverscope® exam

Participants will undergo a LiverScope® examination to measure liver proton density fat fraction (PDFF, primary) and T1 and T2 values (exploratory).

DIAGNOSTIC_TEST

MR exam

Participants will undergo an advanced MR examination to measure liver PDFF, T1, T2, and liver stiffness values.

DIAGNOSTIC_TEST

FibroScan® exam (optional)

Participants may undergo a FibroScan® exam (optional) to evaluate liver fat and liver stiffness.

OTHER

Blood draw

Participants will undergo a blood draw (approximately 10 mL) for measurement of CBC, platelets, and complete metabolic panel with transaminases.

OTHER

Body measurements

Participants will have their height, weight, waist circumference, and hip circumference measured.

OTHER

Questionnaires

Participants will be asked to fill out questionnaires to collect information about their alcohol consumption, history of cigarette smoking, presence of diabetes, and history of liver disease and medications

Trial Locations (1)

92037

University of California San Diego, La Jolla

All Listed Sponsors
collaborator

Livivos, Inc.

UNKNOWN

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

collaborator

National Institute for Biomedical Imaging and Bioengineering (NIBIB)

NIH

lead

University of California, San Diego

OTHER

NCT05986916 - Accurate Point of Care Liver Disease Diagnostics | Biotech Hunter | Biotech Hunter